,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-04-29 06:35:00,"BostonScientific ( BSX ) reported adjusted earnings per share (after considering certain one-time adjustments other than amortization expense) of 13 cents in the first quarter of 2014, 3 cents ahead of the year-ago adjusted EPS figure.",0.8007205724716187,0.07311849296092987,0.12616091966629028,positive,0.7276020646095276
1,2014-04-29 06:35:00,"However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 20 cents, 25% ahead of the year-ago adjusted number.",0.5856776237487793,0.29867368936538696,0.11564873903989792,positive,0.28700393438339233
2,2014-04-29 06:35:00,This also exceeded the company's adjusted EPS guidance range of 16-18 cents and the Zacks Consensus Estimate of 18 cents.,0.9342744946479797,0.023923270404338837,0.04180222004652023,positive,0.9103512167930603
3,2014-04-29 06:35:00,"Without these adjustments, the company reported net income of $133 million or 10 cents per share in the quarter, a huge increase from the year-ago net loss of $354 million or loss of 26 cents a share, respectively.",0.9491369128227234,0.026401108130812645,0.024461952969431877,positive,0.9227358102798462
4,2014-04-29 06:35:00,"Revenues in the first quarter registered a 1% increase year over year (up 4% at constant exchange rate or CER, excluding divested business) to $1.774 billion.",0.9602586030960083,0.01845134049654007,0.021290019154548645,positive,0.9418072700500488
5,2014-04-29 06:35:00,"The figure missed the Zacks Consensus Estimate of $1.793 billion by a sliver, but remained within the company-provided guidance range of $1.755-$1.805 billion.",0.1395205557346344,0.8034944534301758,0.05698506161570549,negative,-0.6639739274978638
6,2014-04-29 06:35:00,"Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.",0.020252270624041557,0.006100116763263941,0.9736475944519043,neutral,0.014152154326438904
7,2014-04-29 06:35:00,"The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions.",0.028852129355072975,0.00474511319771409,0.9664027690887451,neutral,0.024107016623020172
8,2014-04-29 06:35:00,"Sales in these sub-segments were $497 million (up 1% year over year at CER) and $203 million (up 5% at CER), respectively, during the quarter.",0.9455223679542542,0.017833657562732697,0.03664401173591614,positive,0.927688717842102
9,2014-04-29 06:35:00,"Global sales of coronary stent system (within Interventional Cardiology) were $289 million, down 6.8%.",0.017658263444900513,0.9704263806343079,0.011915411800146103,negative,-0.952768087387085
10,2014-04-29 06:35:00,"The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million.",0.01960044912993908,0.9685952067375183,0.011804265901446342,negative,-0.9489947557449341
11,2014-04-29 06:35:00,"The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.",0.10381655395030975,0.00600202102214098,0.8901814818382263,neutral,0.09781453013420105
12,2014-04-29 06:35:00,CRM reflected a sales decline of 2% to $466 million at CER.,0.01799824833869934,0.9736288785934448,0.008372906595468521,negative,-0.9556306600570679
13,2014-04-29 06:35:00,"Worldwide sales from pacemakers (within CRM) edged down 1% to $127 million, while defibrillators declined 3.1% to $339 million.",0.01773376204073429,0.9719871878623962,0.01027901004999876,negative,-0.9542534351348877
14,2014-04-29 06:35:00,"Electrophysiology sales, on the other hand, improved 68% year over year to $58 million.",0.9585198163986206,0.023112865164875984,0.01836729794740677,positive,0.9354069232940674
15,2014-04-29 06:35:00,"Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments.",0.9060390591621399,0.012852884829044342,0.08110802620649338,positive,0.8931861519813538
16,2014-04-29 06:35:00,"However, the dismal performance of Interventional Cardiology and CRM during the reported quarter proved beyond doubt that the measures have not been enough to counter the ongoing challenges.",0.05450408533215523,0.9287497401237488,0.016746217384934425,negative,-0.8742456436157227
17,2014-04-29 06:35:00,"Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $314 million (up 5% at CER), $125 million (up 8%) and $109 million (up 23%), respectively.",0.8780122399330139,0.017785783857107162,0.10420192033052444,positive,0.8602264523506165
18,2014-04-29 06:35:00,Gross margin grew 255 basis points (bps) year over year to 69.7%.,0.9580157399177551,0.018667923286557198,0.02331625483930111,positive,0.9393478035926819
19,2014-04-29 06:35:00,Adjusted operating margin expanded 173 bps to 19.2% in the quarter.,0.9575353264808655,0.017561636865139008,0.024903014302253723,positive,0.9399737119674683
20,2014-04-29 06:35:00,"During the reported quarter, selling, general and administrative expenses increased 5.5% to $666 million, research and development expenses dropped 6.4% to $191 million and royalty expense was down by 2.4% to $40 million.",0.01854105293750763,0.9691984057426453,0.012260534800589085,negative,-0.9506573677062988
21,2014-04-29 06:35:00,"Boston Scientific exited the first quarter with cash and cash equivalents of $191 million, up from $217 million at the end of fiscal 2013, and had long-term debt of $4.24 billion.",0.9411076307296753,0.017597641795873642,0.04129473492503166,positive,0.9235100150108337
22,2014-04-29 06:35:00,The company generated operating cash flow of $198 million and repurchased 10 million shares for $125 million in the quarter under the existing share repurchase program.,0.3337777853012085,0.008515746332705021,0.6577064990997314,neutral,0.32526203989982605
23,2014-04-29 06:35:00,Boston Scientific increased its 2014 adjusted EPS guidance in the range of 77-82 cents from earlier 75-80 cents (considering all one-time items including amortized expense).,0.938188374042511,0.018163500353693962,0.0436481237411499,positive,0.9200248718261719
24,2014-04-29 06:35:00,Revenues are expected to remain in the range of $7.30-$7.50 billion.,0.08701460063457489,0.007777038495987654,0.9052082896232605,neutral,0.07923756539821625
25,2014-04-29 06:35:00,The current Zacks Consensus Estimate for EPS of 78 cents and revenues of $7.41 billion coincide with the company's outlook.,0.05518507957458496,0.006745029706507921,0.9380698204040527,neutral,0.04844005033373833
26,2014-04-29 06:35:00,"For the second quarter of 2014, adjusted earnings are expected to remain in the band of 18-20 cents per share while the company predicts revenues within $1.84-$1.89 billion.",0.21204334497451782,0.01996065117418766,0.7679959535598755,neutral,0.19208268821239471
27,2014-04-29 06:35:00,"The Zacks Consensus Estimate for EPS stands at 20 cents, while that for revenues is $1.87 billion.",0.017293211072683334,0.038126859813928604,0.9445798993110657,neutral,-0.02083364874124527
28,2014-04-29 06:35:00,"Amid challenging economic conditions, competitive environment, pressure on core segments and currency headwind, Boston Scientific posted a mixed first quarter with earnings beat and revenue miss.",0.019424494355916977,0.9686804413795471,0.011895007453858852,negative,-0.9492559432983398
29,2014-04-29 06:35:00,"For quite a long time, the US defibrillator and stent markets have remained as major overhangs.",0.041719380766153336,0.540097713470459,0.4181828796863556,negative,-0.49837833642959595
30,2014-04-29 06:35:00,"Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.",0.049959488213062286,0.8434693217277527,0.10657114535570145,negative,-0.793509840965271
31,2014-04-29 06:35:00,"Nonetheless, we are also looking forward to the emerging market performance of the company.During the quarter, the company achieved 8% international growth on the back of 22% growth in emerging markets, which represented 9% of total company sales.",0.9468093514442444,0.015584706328809261,0.03760598599910736,positive,0.9312246441841125
32,2014-04-29 06:35:00,"Moreover, Boston Scientific has managed to successfully move on with its strong pipeline of products.",0.9438120126724243,0.014309369027614594,0.04187856614589691,positive,0.9295026659965515
33,2014-04-29 06:35:00,It is also focusing on strategic initiatives to drive growth and profitability.,0.7299309372901917,0.01038542203605175,0.25968360900878906,positive,0.7195455431938171
34,2014-04-29 06:35:00,"These include restructuring initiatives for 2014, targeting suitable acquisitions in areas of unmet medical needs and focus on emerging markets.",0.47518059611320496,0.00873199850320816,0.5160873532295227,neutral,0.4664486050605774
35,2014-04-29 06:35:00,"Currently, Boston Scientific retains a Zacks Rank #3 (Hold).",0.026575138792395592,0.010301409289240837,0.9631235003471375,neutral,0.016273729503154755
36,2014-04-29 06:35:00,"Some of the better-placed Medical stocks are Cardinal Health, Inc. ( CAH ), Hologic Inc. ( HOLX ) and The Cooper Companies Inc. ( COO ), all carrying a Zacks Rank #2 (Buy).",0.6035627126693726,0.049311645328998566,0.3471256196498871,positive,0.5542510747909546
37,2014-04-29 06:35:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
38,2014-04-29 06:35:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
